17 results about "Stomach ulcers" patented technology

The invention discloses a compound preparation capsule and a preparation method thereof, wherein the compound preparation capsule is composed of Vonoprasone or a pharmaceutical salt microtablet thereof, an amoxicillin microtablet and a rifampicin or rifampetine microtablet. The Vonoprazan is a novel potassium ion competitive acid blocker, and the compound preparation capsule is used for treating gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and helicobacter pylori infection and helicobacter pylori infection gastritis in the stomach after early gastric cancer endoscopic therapy. According to the compound preparation capsule, the cure rate of helicobacter pylori can be increased, the drug resistance can be reduced, and a better treatment choice is provided for clinical patients.

The present invention relates to the field of pharmaceutical synthesis. A GLP-1 / Gcg dual-agonist compound is disclosed. The GLP-1 / Gcg dual-agonist compound is used for preparing a pharmaceutical composition for treating disease. Use of the pharmaceutical composition in the preparation of a drug for treating at least one of the following diseases: type-II diabetes, impaired glucose tolerance, type-I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive disorders, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, strokes, inflammatory bowel syndrome and / or dyspepsia or gastric ulcers, hepatic fibrosis disease, and pulmonary fibrosis disease.

The present invention relates to an inhibitor of the Helicobacter pylori (H. pylori) cell purine nucleotide salvage pathway (reserve pathway) for use in the treatment of H. pylori infection and / or the treatment or prevention of a disease associated with this infection, such as gastritis and duodenitis, gastric and duodenal ulcers, as well as gastric cancer and MALT-type lymphoma, as well as pancreatic cancer or neurodegenerative diseases or disorders. The present invention also provides a pharmaceutical composition comprising such an inhibitor of the H. pylori cell purine nucleotide salvage pathway and at least one pharmaceutically acceptable excipient. The present invention further provides a pharmaceutical composition comprising such an inhibitor of the H. pylori cell purine nucleotide salvage pathway, at least one pharmaceutically acceptable excipient and at least one additional drug for the treatment of H. pylori infection, selected in particular from an antibiotic, a proton pump inhibitor and a bismuth salt.

The application relates to the medical technical field, in particular to application of 6-mercapto guanine in preparation of a medicine for preventing and / or treating alcoholic gastric ulcer, experimental results show that the 6-mercapto guanine has remarkable curative effect on peptic ulcer disease and inflammatory bowel disease, can effectively improve mucosal integrity, promote tissue morphology improvement, restore animal body weight, and has a good clinical application prospect.

The present application relates to the field of medicine synthesis, disclose a long-acting dual agonist compound. The tirzepatide derivative described in the application is used for preparing a pharmaceutical composition for treating diseases, the use of the pharmaceutical composition in the preparation of a medicine for treating at least one of the following diseases, the diseases include type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or indigestion or gastric ulcer, liver fibrosis disease and pulmonary fibrosis disease.

The present invention pertains to the use of conjugated deoxynivalenol (DON) in a method to protect an animal against DON induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, liver damage, stomach ulcers and / or kidney damage as a result of the ingestion of DON.

The present invention provides a preparation method for a licoflavone multi-component supramolecular inclusion complex and a gastric retention sustained-release formulation thereof and use thereof, and belongs to the technical field of biopharmaceuticals. The licoflavone multi-component supramolecular inclusion complex provided by the present invention is prepared from 10 parts by weight of licoflavone, 10-30 parts by weight of poloxamer, 10-100 parts by weight of cyclodextrin, and 1-10 parts by weight of hypromellose. The licoflavone multi-component supramolecular inclusion complex and the gastric retention sustained-release formulation thereof of the present invention can significantly improve the solubility of licoflavone in water and the solubility of licoflavone in gastric juice, increase the retention time of licoflavone in the stomach, enable sustained release of the drug, increase the absorption of the drug by the stomach or duodenum, improve the bioavailability, reduce the dosage level and the frequency of administration, and have a significant therapeutic effect on stomach ulcers, etc.

The invention relates to the technical field of biological medicine, and discloses application of salidroside or a product containing the salidroside in preparation of a urease inhibitor. According to the application, the fact that the salidrosin has a good inhibition effect on the helicobacter pylori urease is disclosed for the first time, and the discovery is verified through an in-vitro experiment and a molecular docking technology, so that the salidrosin can be used as a candidate drug for resisting the helicobacter pylori urease, and the helicobacter pylori urease can be used for preparing the helicobacter pylori urease. Furthermore, the compound can be used for preparing medicines for treating and / or preventing related stomach diseases such as gastritis and gastric ulcer.

To provide a novel pharmaceutical composition or dietary supplement consisting of an aqueous oral suspension for preventing and treating stomach ulcers and colon cancer, and to provide a method for preparing the same.SOLUTION: A novel pharmaceutical composition or dietary supplement is characterized by containing a purified extract of a fatty alcohol from beeswax, microcrystalline cellulose, and excipients accepted by a pharmaceutical industry. A method for preparing the suspension is characterized by subjecting the fatty-alcohol extract (also known as fatty alcohol purified extract) to a process to reduce particle size to <1.5 micrometers in the presence of an emulsifying agent, at >1000 rpm. A mixture of the active ingredient and microcrystalline cellulose in a proportion and concentration in which they are formulated causes these components to act synergistically, providing the composition with strong anti-ulcerous and chemoprotective effects.SELECTED DRAWING: None

The present invention pertains to the use of conjugated deoxynivalenol (DON) in a method to protect an animal against DON induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, liver damage, stomach ulcers and / or kidney damage as a result of the ingestion of DON.

The invention relates to the technical field of medical imaging, in particular to a biopsy range positioning method and device for a gastric ulcer image, and the method comprises the steps: obtaining a gastric ulcer image of a to-be-detected patient, carrying out the preprocessing of the gastric ulcer image, and obtaining a gastric ulcer optimized image of the gastric ulcer image; respectively inputting the stomach ulcer optimized image into an ulcer focus detection model and a background target detection model, and outputting a focus segmentation image and a background target of the stomach ulcer optimized image; and fusing the focus segmentation image and the background target, and outputting the ulcer biopsy range positioning and biopsy sequence of the patient to be detected. According to the invention, gastric ulcer focus segmentation is realized, so that a gastric ulcer biopsy range is obtained, and doctors are assisted in biopsy positioning; a coordinate system is constructed through the big bend, the center point of the endoscope body and the center point of the gastric ulcer, the biopsy sequence is judged in combination with logic, and the gastroscope detection efficiency is efficiently improved.

The invention relates to the field of traditional Chinese medicine formulas, and particularly discloses a traditional Chinese medicine formula for treating stomach diseases and a preparation method and application thereof. The invention discloses a traditional Chinese medicine formula for treating stomach diseases. The traditional Chinese medicine formula comprises the following components by weight: 5-15g of deep-fried bighead atractylodes rhizome, 3-10g of cassia twig, 10-15g of rice sprout, 1.5-5g of coptis chinensis, 3-15g of fructus forsythiae, 15-30g of dandelion, 3-10g of mangnolia officinalis, 1-3g of agilawood, 15-30g of astragalus membranaceus, 3-9g of poria cocos, 3-9g of elecampane, 3-9g of fingered citron, 3-10g of octopus, 10-15g of pearl, 3-10g of pericarpium citri reticulatae, 3-9g of frankincense, 3-9g of myrrh, 5-10g of trogopterus dung, 3-9g of stigma croci, 10-15g of red yeast rice, 2-10g of liquorice, 3-9g The traditional Chinese medicine is prepared from 0.5-1.0 g of benzoin, 0.03-1 g of borneol, 6-15 g of radix salviae miltiorrhizae, 3-9 g of radix curcumae, 1-3 g of clove, 3-6 g of amomum cardamomum, 3-10 g of rhizoma nardostachyos, 3-9 g of Chinese yam, 5-10 g of radix paeoniae alba, 3-9 g of curcuma zedoary and a small amount The preparation method of the Sanwei capsule comprises the following steps: S1, preparing thick paste; s2, grinding into powder; s3, performing granulation; and S4, preparing the capsule. The Sanwei powder and the Sanwei capsule can be used for treating various types of gastritis, gastric ulcer and gastric erosion, and have the advantages of good effect and small side effect.

The invention relates to a herbal preparation that supports the treatment of gastric and duodenal ulcers and gastroesophageal reflux, along with a process for preparing this preparation, which involves a rational combination of natural herbal ingredients, optimal extraction techniques, and strict control of product content and quality. Specifically, the preparation is made from a mixture of herbs including White Peony (Radix Paeoniae lactiflorae), Ginger-processed Pinellia (Rhizoma Pinelliae praeparatum), Tangerine Peel (Pericarpium Citri reticulatae perenne), Chinese Yam (Tuber Dioscoreae persimilis), Saussurea lappae (Radix Saussureae lappae), and Gardenia Fruit (Fructus Gardeniae), with the ratio adjusted within an optimal range to maximize synergistic effects, combined with safe pharmaceutical additives to stabilize the dosage form and increase absorption.Preclinical trial results showed that the preparation significantly reduced the degree of gastric mucosal damage in an experimental ulcer model, while also reducing damage and improving esophageal morphology in a reflux model, with observed effects better than the untreated model and comparable to the control group Nexium 10 mg. These results demonstrate the preparation's ability to protect the mucosa, support damage recovery, and reduce inflammation. Furthermore, the optimized manufacturing process in terms of solvent, extraction conditions, and impurity removal resulted in a pure, stable herbal extract with good bioavailability, thus providing high therapeutic efficacy and safety.

The invention discloses an application of a ferroptosis inhibitor in resisting SPEM, relates to the technical field of medicine, and has the technical key points that in-vivo injection of the ferroptosis inhibitor Ferrostatin-1 can obviously improve the GPX4 level of gastric mucosa tissues of mice and inhibit the pathological process of ferroptosis of gastric mucosa wall cells, and the application of the ferroptosis inhibitor Ferrostatin-1 in resisting SPEM is found. Therefore, the expression of inflammatory factors of gastric mucosa tissues of mice is effectively reduced, the SPEM index is remarkably reduced, and the pathological processes of chronic gastric ulcer and gastric cancer in the early stage are effectively inhibited; in-vivo and in-vitro experiments prove that the ferroptosis inhibitor Ferrostatin-1 can be used for treating chronic gastric ulcer and early gastric cancer, and a new thought is provided for research, development and innovation of drugs for chronic gastric ulcer and early gastric cancer.

The present invention relates to the field of pharmaceutical synthesis. A GLP-1 / Gcg dual-agonist compound is disclosed. The GLP-1 / Gcg dual-agonist compound is used for preparing a pharmaceutical composition for treating disease. Use of the pharmaceutical composition in the preparation of a drug for treating at least one of the following diseases: type-II diabetes, impaired glucose tolerance, type-I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive disorders, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, strokes, inflammatory bowel syndrome and / or dyspepsia or gastric ulcers, hepatic fibrosis disease, and pulmonary fibrosis disease.

The present invention belongs to the field of biopharmaceutical technology, and specifically relates to the use of tripeptides in the preparation of drugs for treating and / or preventing mucosal or skin damage. The present invention provides the use of a peptide or a salt thereof having an amino acid sequence of valine-proline-leucine in the preparation of drugs for treating and / or preventing diseases caused by mucosal damage or skin damage. The peptides of the present invention can effectively promote the repair of digestive tract mucosal damage and reduce the development of gastrointestinal disease pathology of acute and chronic gastritis and digestive tract ulcers. Pharmacological experimental results show that the peptides of the present invention have significant preventive and therapeutic effects on ethanol-induced mouse gastric ulcer models, and the application of the present invention provides a new idea and strategy for clinical diseases caused by mucosal damage or skin damage.

The invention relates to a composition which comprises glycosaminoglycans, a polysaccharide and a monosaccharide derivative of glucose. The invention also relates to its use as a medicament and, particularly, to its use as a gastroprotector for the treatment of gastric irritation, stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis and stomach inflammation and for the prevention of stress ulcers and to the use of composition as food supplement of complementary feed.